Neuland Laboratories

₹19,836As of Sun 8 Nov 2026, 12:00 UTC
NSE:NEULANDLABHealthcare
Country India
PE (Fwd) 54.00
TSR 10Y CAGR 35.28%
Div yield 0.17%
ROE —
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.34
PE TTM 69.92
TSR TTM 20.64%
Mkt cap ₹260.7B
ROIC —
SE Grade™
Value
Quality
Moat
1Y Price
Reference
₹22,048
11.15%
(84.50%)
Price above Reference Value
FY23
FY24
FY25
FY26
Earnings per share₹
127.45
233.89
202.74
283.71
156.23%
83.51%
(13.32%)
39.94%
Revenue₹B
11.91
15.59
14.77
20.23
25.20%
30.81%
(5.24%)
36.98%
TTM
FYE 31 Mar INR
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
FY2027E
Trend
5Y
10Y
Peers
20.23
Revenue₹B
—
—
—
—
—
9.517
11.91
15.59
14.77
20.23
22.98
20.75%
20.75%
3
36.98
Revenue growth%
—
—
—
—
—
—
25.20
30.81
(5.24)
36.98
13.62
28.00
—
97
53.18
Gross margin%
—
—
—
—
—
41.84
48.49
52.92
49.18
53.18
53.39
49.18
49.18
31
24.12
Operating margin%
—
—
—
—
—
10.10
19.35
25.88
17.95
24.12
24.41
19.35
19.35
86
17.99
Net margin%
—
—
—
—
—
6.71
13.72
19.25
17.61
17.99
18.21
17.61
17.61
79
69.92
P/E ratio (avg)x
—
—
—
—
—
35.65
11.46
17.56
58.59
48.35
60.80
35.65
35.65
39
52.15
EV/EBITx
—
—
—
—
—
23.68
8.129
13.06
57.51
36.06
45.35
23.68
23.68
22
—
FCF yield (avg)%
—
—
—
—
—
—
—
—
—
—
—
—
—
24
—
FCF margin%
—
—
—
—
—
—
—
—
—
—
—
—
—
46
—
FCF / Net incomex
—
—
—
—
—
—
—
—
—
—
—
—
—
23
—
ROIC%
—
—
—
—
—
—
—
—
—
—
—
—
—
90
—
Return on equity%
—
—
—
—
—
—
—
—
—
—
—
—
—
93
—
Return on assets%
—
—
—
—
—
—
—
—
—
—
—
—
—
97
283.71
EPS₹
—
—
—
—
—
49.74
127.45
233.89
202.74
283.71
326.28
54.54%
54.54%
—
39.94
EPS growth%
—
—
—
—
—
—
156.21
83.51
(13.32)
39.94
15.00
61.73
—
74
—
Bookvalue per sh₹
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
FCF per share₹
—
—
—
—
—
—
—
—
—
—
—
—
—
—
34.00
Dividend per sh₹
—
—
—
—
—
5.00
10.00
14.00
12.00
34.00
37.92
61.48%
61.48%
—
0.17
Div yield (avg)%
—
—
—
—
—
0.28
0.68
0.34
0.10
0.25
0.19
0.28
0.28
0
11.98
Payout ratio%
—
—
—
—
—
10.05
7.85
5.99
5.92
11.98
11.62
7.85
7.85
10
12.83
Shares (diluted)M
—
—
—
—
—
12.83
12.83
12.83
12.83
12.83
◌12.83
—
—
79
—
Buyback yield%
—
—
—
—
—
—
—
—
—
—
◌—
—
—
79
—
D/E ratiox
—
—
—
—
—
—
—
—
—
—
—
—
—
55
254.5
Enterprise value₹B
—
—
—
—
—
22.75
18.74
52.69
152.4
176.0
254.5
66.77%
66.77%
47
—
LT debt₹M
—
—
—
—
—
—
—
—
—
—
—
—
—
23
Peers (US$2.691B)
Cap (US$)
PE
3.379B
76.44x
2.100B
27.85x
2.744B
40.61x
Capital
TTM
5Y
10Y
Leveragex
—
—
—
EBIT/Intx
26.10
26.10
26.10
Own earn%
—
—
—
Sh yield%
0.17
0.29
0.29
Owners
Insiders/Inst%
11.30
24.52
Short interest%
—
SBC / revenue%
—
Record
10Y
Profitable years
5/5
Revenue growth years
3/4
EPS growth years
3/4
Dividend streakyrs
0
Op margin range%
10–26
$1 testx
—
Incr. ROIC%
—

Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services.

Growth vs revenue
Latest
Trend
4Y CAGR
Rel growth
Revenue
₹20.23B
20.75%
1.00×
Cost of revenue
₹9.471B
14.37%
0.80×
Operating expenses
₹5.878B
18.11%
0.92×
Revenue by region
No breakdown available
Reinvestment returns
n/m
Trend
Reinvestment rate
n/m
-
Return on capital
n/m
-
Spread over hurdle
n/m
-